Reltecimod FDA Approval Status

Last updated by Judith Stewart, BPharm on Jan 6, 2021.

FDA Approved: No
Generic name: reltecimod
Company: Atox Bio
Treatment for: Organ Dysfunction or Failure in Patients with Necrotizing Soft Tissue Infection

Reltecimod is an immunomodulator peptide in development for the treatment of suspected organ dysfunction or failure in patients with necrotizing soft tissue infection (NSTI).

Development timeline for reltecimod

Date	Article
Dec 10, 2020	Atox Bio Announces FDA Acceptance to File the NDA for Reltecimod to Treat Suspected Organ Dysfunction or Failure in Patients with Necrotizing Soft Tissue Infection ("Flesh-Eating Disease")
Jul 10, 2020	Atox Bio Announces a Positive Effect of Reltecimod on Resolution of Organ Dysfunction in Phase 3 ACCUTE Trial for Patients with Necrotizing Soft Tissue Infection (“Flesh Eating Disease”)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer